The Japanese Journal of Urology
Online ISSN : 1884-7110
Print ISSN : 0021-5287
ISSN-L : 0021-5287
CLINICAL EVALUATION OF SERUM BASIC FETOPROTEIN FOR PROSTATIC CANCER
Comparative Study with PAP, γ-Sm and PSA
Akinobu GotohYoshihito MizunoAtsushi Takenaka[in Japanese]Kazuo GohjiTakayoshi OgawaSoichi ArakawaSadao KamidonoKenji HaradaKuhei HirookaNoboru ShimataniTakaaki InoueHirokazu TanakaKeiichi UmezuTakashi MatsuiYouko InabaTakehiro IzumiYuuji YamadaNoboru ItoYasuyuki OkamotoHiroshi OkadaKenji MinayoshiMasaru IshiiHitoshi NagataNozomu YamanakaHiroshi MaedaTateo NakanishiHideki Uehara
Author information
JOURNALS FREE ACCESS

1991 Volume 82 Issue 3 Pages 467-472

Details
Abstract

The clinical significance of serum basic fetoprotein (BFP) in prostatic cancer was investigated together with serum prostatic acid phosphatase (PAP), γ-seminoprotein (γ-Sm) and prostate specific antigen (PA).
Investigated in this study were 40 patients with prostatic cancer, ranging in age from 50 to 85 years (mean age: 69.5 years). According to clinical staging, 3 cases (7.5%) had a stage A disease, 10 cases (25.0%) a stage B disease, 7 cases (17.5%) a stage C disease, and 20 cases (50.0%) a stage D disease. The positive rates for serum BFP, PAP, γ-Sm, and PSA were 60.0, 45.0, 63.6, and 68.4%, respectively, and these rates increased as the stage advanced. The above results suggest that BFP is the most useful marker of the four for monitoring prostatic cancer.
In a combination assay of these four markers, 29 (87.9%) of 33 patients with prostatic cancer could be diagnosed by observing an elevated serum level in one of the markers. This suggests that a combination assay of BFP, PAP, γ-Sm and PSA in patients with prostatic cancer is useful for diagnosis and monitoring of the disease.

Information related to the author
© Japanese Urological Association
Previous article Next article
feedback
Top